Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sensus Healthcare (SRTS) Research & Development (2016 - 2025)

Sensus Healthcare has reported Research & Development over the past 10 years, most recently at $1.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 20.56% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $7.8 million, up 84.49%, while the annual FY2025 figure was $7.8 million, 84.49% up from the prior year.
  • Research & Development for Q4 2025 was $1.9 million at Sensus Healthcare, up from $1.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $2.6 million in Q1 2025 and troughed at $661000.0 in Q1 2021.
  • A 5-year average of $1.1 million and a median of $925500.0 in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: tumbled 46.04% in 2021 and later soared 181.43% in 2025.
  • Year by year, Research & Development stood at $1.1 million in 2021, then rose by 4.7% to $1.2 million in 2022, then tumbled by 41.54% to $677000.0 in 2023, then skyrocketed by 130.58% to $1.6 million in 2024, then grew by 20.56% to $1.9 million in 2025.
  • Business Quant data shows Research & Development for SRTS at $1.9 million in Q4 2025, $1.8 million in Q3 2025, and $1.5 million in Q2 2025.